What it's for (Indications)
- Galantamine HBr (e.
- g.
- , Dementio ER) is indicated for the symptomatic treatment of mild to moderate dementia of the Alzheimer's type.
- Its efficacy has been rigorously established in randomized, placebo-controlled clinical trials, demonstrating modest but statistically significant improvements in cognitive function and global clinical status.
- This medication is not a cure for Alzheimer's disease but aims to alleviate some of the cognitive and functional decline associated with the condition.
- The decision to initiate and continue treatment should be based on a thorough clinical assessment, considering the patient's individual response and tolerability, and should be overseen by a healthcare professional experienced in the diagnosis and management of Alzheimer's dementia.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for galantamine HBr extended-release capsules (e.g., Dementio ER) is 8 mg once daily, administered preferably with the evening meal. After a minimum of 4 weeks of treatment, the dosage should be increased to 16 mg once daily, provided the patient has tolerated the initial dose well and a clinical response is deemed appropriate. A further increase to 24 mg once daily, which is the maximum recommended daily dose, may be considered after an additional 4 weeks at the 16 mg dose, again contingent on tolerability and clinical benefit. Doses exceeding 24 mg per day have not demonstrated additional therapeutic benefit and are associated with an increased incidence of adverse reactions. For patients with moderate hepatic or renal impairment (creatinine clearance of 9-59 mL/min or Child-Pugh score of 7-9), the maximum daily dose should not exceed 16 mg. Dose adjustments are crucial for optimal safety and efficacy. |
Safety & Warnings
Common Side Effects
- Galantamine HBr is commonly associated with a range of dose-dependent adverse effects, predominantly affecting the gastrointestinal system.
- Frequent side effects include nausea, vomiting, diarrhea, abdominal pain, and anorexia, which can sometimes lead to clinically significant weight loss.
- Other commonly reported adverse reactions involve the central nervous system, such as dizziness, headache, and fatigue.
- More serious, albeit less common, adverse effects include significant bradycardia, syncope, and in rare instances, atrial fibrillation, particularly in individuals with pre-existing cardiac conduction abnormalities.
- There have also been post-marketing reports of seizures, urinary tract obstruction, and exacerbation of pulmonary conditions such as asthma or chronic obstructive pulmonary disease (COPD).
- Patients and caregivers should be advised to report any severe or persistent side effects to their healthcare provider for evaluation and potential management, which may include dose reduction or discontinuation.
Serious Warnings
- Black Box Warning: Galantamine HBr (e.g., Dementio ER) does not carry a formal FDA Black Box Warning. However, healthcare providers must be acutely aware of several serious warnings and precautions associated with its use, particularly in vulnerable patient populations. Patients with pre-existing cardiac conditions, such as sick sinus syndrome, uncompensated heart failure, or significant bradycardia, are at an increased risk of severe bradycardia and syncope due to the cholinergic effects of galantamine. The potential for gastrointestinal adverse events, including an increased risk of gastrointestinal bleeding, should be considered, especially in patients with a history of peptic ulcer disease or those on concomitant NSAIDs. Other significant concerns include the potential for exacerbation of asthma or chronic obstructive pulmonary disease (COPD), bladder outflow obstruction, and the induction or exacerbation of seizures. These serious risks underscore the importance of careful patient selection, meticulous monitoring, and gradual dose titration to mitigate potential harm and ensure patient safety throughout the course of therapy.
- Galantamine HBr should be used with extreme caution in patients with a history of cardiac conduction abnormalities, including sick sinus syndrome, uncompensated heart failure, or those concurrently receiving medications that significantly slow heart rate, due to the potential for exacerbation of bradycardia, syncope, and other cholinergic-mediated cardiac events.
- The drug can increase gastric acid secretion, increasing the risk for patients with a history of peptic ulcer disease or those on concomitant non-steroidal anti-inflammatory drugs (NSAIDs).
- Cholinesterase inhibitors, including galantamine, can cause bladder outflow obstruction and should be used cautiously in patients with a history of prostatic hypertrophy or other urinary tract obstructions.
- Furthermore, due to its cholinergic activity, galantamine may enhance succinylcholine-type muscle relaxation during anesthesia, and it has the potential to induce or exacerbate seizure activity in patients with a history of seizure disorders.
- Careful monitoring and dose adjustments are essential in these vulnerable populations.
How it Works (Mechanism of Action)
Galantamine HBr primarily exerts its therapeutic effects through a dual mechanism of action. It acts as a selective, reversible, and competitive inhibitor of acetylcholinesterase (AChE), the enzyme responsible for the breakdown of acetylcholine (ACh) in the synaptic cleft. By inhibiting AChE, galantamine increases the concentration of ACh, thereby enhancing cholinergic neurotransmission in the central nervous system. This action is particularly relevant in Alzheimer's disease, where a marked deficiency in cholinergic function contributes to cognitive decline. Additionally, galantamine acts as an allosteric potentiator of nicotinic acetylcholine receptors (nAChRs). This unique secondary mechanism modulates the sensitivity of these receptors to ACh, leading to an enhanced release of ACh and potentially other neurotransmitters, further contributing to its cognitive-enhancing properties. This dual action is believed to provide a more comprehensive approach to managing cholinergic deficits in Alzheimer's patients.
Commercial Brands (Alternatives)
No other brands found for this formula.